Document_and_Entity_Informatio
Document and Entity Information | 3 Months Ended | |
Mar. 31, 2015 | Apr. 30, 2015 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | FALSE | |
Document Period End Date | 31-Mar-15 | |
Document Fiscal Year Focus | 2015 | |
Document Fiscal Period Focus | Q1 | |
Trading Symbol | XENT | |
Entity Registrant Name | Intersect ENT, Inc. | |
Entity Central Index Key | 1271214 | |
Current Fiscal Year End Date | -19 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Common Stock, Shares Outstanding | 23,663,022 |
Condensed_Balance_Sheets
Condensed Balance Sheets (USD $) | Mar. 31, 2015 | Dec. 31, 2014 | |
In Thousands, unless otherwise specified | |||
Current assets: | |||
Cash and cash equivalents | $14,224 | $13,403 | [1] |
Short-term investments, available-for-sale | 28,682 | 35,040 | [1] |
Accounts receivable, net | 7,998 | 8,337 | [1] |
Inventory | 2,826 | 2,547 | [1] |
Prepaid expenses and other current assets | 1,268 | 951 | [1] |
Total current assets | 54,998 | 60,278 | [1] |
Property and equipment, net | 1,779 | 1,474 | [1] |
Other non-current assets | 1,149 | 1,201 | [1] |
Total assets | 57,926 | 62,953 | [1] |
Current liabilities: | |||
Accounts payable | 1,974 | 2,128 | [1] |
Accrued compensation | 4,294 | 5,085 | [1] |
Other current liabilities | 878 | 898 | [1] |
Total current liabilities | 7,146 | 8,111 | [1] |
Deferred rent | 1,098 | 1,030 | [1] |
Total liabilities | 8,244 | 9,141 | [1] |
Commitments and contingencies (note 10) | [1] | ||
Preferred stock, $0.001 par value; Authorized shares: 10,000 at March 31, 2015 and December 31, 2014; Issued and outstanding shares: none | [1] | ||
Common stock, $0.001 par value; Authorized shares: 150,000 at March 31, 2015 and December 31, 2014; Issued and outstanding shares: 23,633 at March 31, 2015 and 23,379 at December 31, 2014 | 24 | 23 | [1] |
Additional paid-in capital | 151,617 | 150,410 | [1] |
Accumulated deficit | -101,959 | -96,621 | [1] |
Total stockholders' equity | 49,682 | 53,812 | [1] |
Total liabilities and stockholders' equity | $57,926 | $62,953 | [1] |
[1] | Amounts have been derived from the December 31, 2014 audited financial statements included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. |
Condensed_Balance_Sheets_Paren
Condensed Balance Sheets (Parenthetical) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 | |
Statement of Financial Position [Abstract] | |||
Preferred stock, par value | $0.00 | $0.00 | [1] |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 | [1] |
Preferred stock, shares issued | 0 | 0 | [1] |
Preferred stock, shares outstanding | 0 | 0 | [1] |
Common stock, par value | $0.00 | $0.00 | [1] |
Common stock, shares authorized | 150,000,000 | 150,000,000 | [1] |
Common stock, shares issued | 23,633,000 | 23,379,000 | [1] |
Common stock, shares outstanding | 23,633,000 | 23,379,000 | [1] |
[1] | Amounts have been derived from the December 31, 2014 audited financial statements included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. |
Condensed_Statements_of_Operat
Condensed Statements of Operations and Comprehensive Loss (USD $) | 3 Months Ended | |||
In Thousands, except Per Share data, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 | ||
Income Statement [Abstract] | ||||
Revenue | $13,372 | $7,497 | ||
Cost of sales | 2,792 | 2,360 | ||
Gross profit | 10,580 | 5,137 | ||
Operating expenses: | ||||
Selling, general and administrative | 12,620 | 6,658 | ||
Research and development | 3,326 | 2,577 | ||
Total operating expenses | 15,946 | 9,235 | ||
Loss from operations | -5,366 | -4,098 | ||
Interest and other income | 29 | 1 | ||
Interest and other expense | -1 | -312 | ||
Net loss and comprehensive loss | ($5,338) | ($4,409) | ||
Net loss per share, basic and diluted | ($0.23) | ($2.49) | ||
Weighted average common shares used to compute net loss per share, basic and diluted | 23,488 | [1] | 1,773 | [1] |
[1] | In connection with the Company's IPO in July 2014, the convertible preferred stock outstanding was converted into common stock on a one-for-one basis. |
Condensed_Statements_of_Cash_F
Condensed Statements of Cash Flows (USD $) | 3 Months Ended | ||
In Thousands, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 | |
Operating activities: | |||
Net loss | ($5,338) | ($4,409) | |
Adjustments to reconcile net loss to cash used in operating activities: | |||
Depreciation and amortization | 140 | 135 | |
Stock-based compensation expense | 778 | 182 | |
Amortization of net investment premium paid | 96 | ||
Change in fair value of convertible preferred stock warrants | 286 | ||
Forgiveness of notes receivable from related party | 100 | ||
Loss on disposal of fixed assets | 2 | ||
Changes in operating assets and liabilities: | |||
Accounts receivable, net | 339 | -182 | |
Inventory | -279 | -266 | |
Prepaid expenses and other current assets | -317 | -96 | |
Other non-current assets | -95 | ||
Accounts payable | -255 | 189 | |
Accrued compensation | -791 | -546 | |
Other current liabilities and deferred rent | 55 | 156 | |
Net cash used in operating activities | -5,570 | -4,546 | |
Investing activities: | |||
Purchases of short-term investments | -8,286 | ||
Maturities of short-term investments | 14,548 | ||
Purchases of property and equipment | -295 | -136 | |
Net cash provided by (used in) investing activities | 5,967 | -136 | |
Financing activities: | |||
Proceeds from issuance of common stock | 424 | 36 | |
Repayments related to equipment loans | -163 | ||
Repayments related to capital lease financing | -7 | ||
Net cash provided by (used in) financing activities | 424 | -134 | |
Net increase (decrease) in cash and cash equivalents | 821 | -4,816 | |
Cash and cash equivalents: | |||
Beginning of the period | 13,403 | [1] | 12,294 |
End of the period | $14,224 | $7,478 | |
[1] | Amounts have been derived from the December 31, 2014 audited financial statements included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. |
Organization
Organization | 3 Months Ended | |
Mar. 31, 2015 | ||
Accounting Policies [Abstract] | ||
Organization | 1 | Organization |
Description of Business | ||
Intersect ENT, Inc. (the “Company”) is incorporated in the state of Delaware and its facilities are located in Menlo Park, California. The Company is a commercial stage drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions. The Company’s sole commercial products are the PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company received approval from the U.S. Food and Drug Administration (“FDA”) for PROPEL in August 2011 and for PROPEL mini in November 2012. In the first half of 2013, the Company began scaling its U.S. direct commercial presence and currently markets its products only in the United States. | ||
Liquidity and Business Risks | ||
As of March 31, 2015, the Company had cash, cash equivalents and short-term investments of $42.9 million, and an accumulated deficit of $102.0 million. The Company expects its cash, cash equivalents and short-term investments will be sufficient to fund its operations through at least the next twelve months. |
Summary_of_Significant_Account
Summary of Significant Accounting Policies | 3 Months Ended | |
Mar. 31, 2015 | ||
Accounting Policies [Abstract] | ||
Summary of Significant Accounting Policies | 2 | Summary of Significant Accounting Policies |
Basis of Preparation | ||
The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”). | ||
The interim financial data as of March 31, 2015, is unaudited and is not necessarily indicative of the results for the full year. In the opinion of the Company’s management, the interim data includes only normal and recurring adjustments necessary for a fair statement of the Company’s financial results for the three months ended March 31, 2015 and 2014. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. | ||
The accompanying condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K (“Annual Report”) for the year ended December 31, 2014 filed with the SEC on March 11, 2015. | ||
1-for-4 Reverse Stock Split | ||
In July 2014, the board of directors and stockholders approved, and the Company filed, an amended and restated certificate of incorporation effecting a 1-for-4 reverse stock split of common stock and all convertible preferred stock. The par value of the common and convertible preferred stock was not adjusted as a result of the reverse stock split. All issued and outstanding common stock, convertible preferred stock, warrants for preferred stock, stock options and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. | ||
Initial Public Offering | ||
In July 2014, the Company completed its IPO by issuing 5,750,000 shares of common stock, including 750,000 shares pursuant to the full exercise by the underwriters of their option to purchase additional shares, at an offering price of $11.00 per share, for net proceeds of $55.8 million, after deducting underwriting discounts and commissions of $4.5 million and offering expenses of $3.0 million. In connection with the IPO, the Company’s outstanding shares of convertible preferred stock were automatically converted into 15,703,875 shares of common stock and warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for 53,357 shares of common stock, resulting in the reclassification of the related redeemable convertible preferred stock warrant liability of $0.4 million to additional paid-in capital. | ||
Use of Estimates | ||
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its common stock valuation and related stock-based compensation, the valuations of the convertible preferred stock warrant liability, convertible preferred stock financing option, as well as certain accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. | ||
Significant Accounting Policies | ||
There have been no significant changes to the accounting policies during the three months ended March 31, 2015, as compared to the significant accounting policies described in Note 2 of the “Notes to Financial Statements” in the Company’s audited financial statements included in its Annual Report. | ||
Comprehensive Loss | ||
Comprehensive loss comprises net loss and other comprehensive income (loss). The Company has no components of other comprehensive income (loss). Therefore net loss equals comprehensive loss for all periods presented. | ||
Recent Accounting Pronouncements | ||
There have been no significant changes to the recent accounting pronouncements during the three months ended March 31, 2015, as compared to the recent accounting pronouncements described in Note 2 of the “Notes to Financial Statements” in the Company’s audited financial statements included in its Annual Report. |
Composition_of_Certain_Financi
Composition of Certain Financial Statement Items | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||
Composition of Certain Financial Statement Items | 3 | Composition of Certain Financial Statement Items | |||||||
Inventory (in thousands): | |||||||||
March 31, | December 31, | ||||||||
2015 | 2014 | ||||||||
Raw materials | $ | 709 | $ | 761 | |||||
Work-in-process | 146 | 141 | |||||||
Finished goods | 1,971 | 1,645 | |||||||
$ | 2,826 | $ | 2,547 | ||||||
Property and Equipment (in thousands): | |||||||||
March 31, | December 31, | ||||||||
2015 | 2014 | ||||||||
Computer equipment and software | $ | 616 | $ | 546 | |||||
Furniture and office equipment | 184 | 158 | |||||||
Laboratory equipment | 2,494 | 2,276 | |||||||
Leasehold improvements | 254 | 128 | |||||||
3,548 | 3,108 | ||||||||
Less: accumulated depreciation and amortization | (1,769 | ) | (1,634 | ) | |||||
$ | 1,779 | $ | 1,474 | ||||||
Depreciation and capital lease amortization expenses was $0.1 million during each of the three months ended March 31, 2015 and 2014. |
Cash_Cash_Equivalents_and_Shor
Cash, Cash Equivalents and Short-term Investments | 3 Months Ended | ||||||||||||||||||||||||||||||||
Mar. 31, 2015 | |||||||||||||||||||||||||||||||||
Cash and Cash Equivalents [Abstract] | |||||||||||||||||||||||||||||||||
Cash, Cash Equivalents and Short-term Investments | 4 | Cash, Cash Equivalents and Short-term Investments | |||||||||||||||||||||||||||||||
The following is a summary of cash, cash equivalents and short-term investments, available-for-sale, by type of instrument (in thousands): | |||||||||||||||||||||||||||||||||
March 31, | December 31, | ||||||||||||||||||||||||||||||||
2015 | 2014 | ||||||||||||||||||||||||||||||||
Amortized | Gross Unrealized | Estimated | Amortized | Gross Unrealized | Estimated | ||||||||||||||||||||||||||||
Cost | Gains | Losses | Fair Value | Cost | Gains | Losses | Fair Value | ||||||||||||||||||||||||||
Cash | $ | 2,360 | $ | — | $ | — | $ | 2,360 | $ | 1,971 | $ | — | $ | — | $ | 1,971 | |||||||||||||||||
Money market funds | 11,864 | — | — | 11,864 | 11,432 | — | — | 11,432 | |||||||||||||||||||||||||
Corporate debt securities | 24,938 | 1 | (6 | ) | 24,933 | 28,797 | 3 | (10 | ) | 28,790 | |||||||||||||||||||||||
Commercial paper | 3,744 | 5 | — | 3,749 | 6,243 | 7 | — | 6,250 | |||||||||||||||||||||||||
$ | 42,906 | $ | 6 | $ | (6 | ) | $ | 42,906 | $ | 48,443 | $ | 10 | $ | (10 | ) | $ | 48,443 | ||||||||||||||||
Reported as: | |||||||||||||||||||||||||||||||||
Cash and cash equivalents | $ | 14,224 | $ | 13,403 | |||||||||||||||||||||||||||||
Short-term investments, available-for-sale | 28,682 | 35,040 | |||||||||||||||||||||||||||||||
$ | 42,906 | $ | 48,443 | ||||||||||||||||||||||||||||||
Management has the intent and ability, if necessary, to liquidate any of the Company’s investments in order to meet the Company’s liquidity needs in the next 12 months. Accordingly, investments with contractual maturities greater than one year from the date of purchase, if any, are available-for-sale and classified as short-term on the accompanying balance sheets. As of March 31, 2015 and December 31, 2014, the Company had no investments with a maturity of greater than one year. | |||||||||||||||||||||||||||||||||
Based on an evaluation of securities that have been in a loss position, the Company did not recognize any other-than-temporary impairment charges during the three months ended March 31, 2015 and year ended December 31, 2014. The Company considered various factors which included a credit and liquidity assessment of the underlying securities and the Company’s intent and ability to hold the underlying securities until the estimated date of recovery of its amortized cost. |
Fair_Value_of_Financial_Instru
Fair Value of Financial Instruments | 3 Months Ended | ||||||||||||||||||||||||||||||||
Mar. 31, 2015 | |||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||
Fair Value of Financial Instruments | 5 | Fair Value of Financial Instruments | |||||||||||||||||||||||||||||||
The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, short-term investments, the convertible preferred stock warrant liability and the convertible preferred stock financing option. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value: | |||||||||||||||||||||||||||||||||
Level 1 | – | Observable inputs such as quoted prices (unadjusted) for identical assets or liabilities in active markets. | |||||||||||||||||||||||||||||||
Level 2 | – | Include other inputs that are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be derived from observable market data. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, foreign exchange rates, and credit ratings. | |||||||||||||||||||||||||||||||
Level 3 | – | Unobservable inputs that are supported by little or no market activities, which would require the Company to develop its own assumptions. | |||||||||||||||||||||||||||||||
The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. | |||||||||||||||||||||||||||||||||
Cash, Cash Equivalents and Short-term Investments | |||||||||||||||||||||||||||||||||
The following is a summary of cash, cash equivalents and short-term investments, available-for-sale, by type of instrument measured at fair value on a recurring basis (in thousands): | |||||||||||||||||||||||||||||||||
March 31, | December 31, | ||||||||||||||||||||||||||||||||
2015 | 2014 | ||||||||||||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||||||||
Cash | $ | 2,360 | $ | — | $ | — | $ | 2,360 | $ | 1,971 | $ | — | $ | — | $ | 1,971 | |||||||||||||||||
Money market funds | 11,864 | — | — | 11,864 | 11,432 | — | — | 11,432 | |||||||||||||||||||||||||
Corporate debt securities | — | 24,933 | — | 24,933 | — | 28,790 | — | 28,790 | |||||||||||||||||||||||||
Commercial paper | — | 3,749 | — | 3,749 | — | 6,250 | — | 6,250 | |||||||||||||||||||||||||
$ | 14,224 | $ | 28,682 | $ | — | $ | 42,906 | $ | 13,403 | $ | 35,040 | $ | — | $ | 48,443 | ||||||||||||||||||
Reported as: | |||||||||||||||||||||||||||||||||
Cash and cash equivalents | $ | 14,224 | $ | 13,403 | |||||||||||||||||||||||||||||
Short-term investments, available-for-sale | 28,682 | 35,040 | |||||||||||||||||||||||||||||||
$ | 42,906 | $ | 48,443 | ||||||||||||||||||||||||||||||
There were no transfers in and out of Level 1 and Level 2 fair value measurements during the three months ended March 31, 2015 and year ended December 31, 2014. | |||||||||||||||||||||||||||||||||
Convertible Preferred Stock Warrant Liability | |||||||||||||||||||||||||||||||||
The following table sets forth a summary of the changes in the estimated fair value of the Company’s convertible preferred stock warrants, which represents financial instruments with valuations classified as Level 3. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. However, Level 3 financial instruments typically include, in addition to the unobservable inputs, observable inputs (that is, components that are actively quoted and can be validated to external sources). Accordingly, the expense in the table below includes changes in fair value due in part to observable factors that are part of the Level 3 methodology (in thousands): | |||||||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||||||
March 31, | |||||||||||||||||||||||||||||||||
2015 (1) | 2014 | ||||||||||||||||||||||||||||||||
Beginning of the period | $ | — | $ | 237 | |||||||||||||||||||||||||||||
Exercised | — | (29 | ) | ||||||||||||||||||||||||||||||
Change in fair value | — | 286 | |||||||||||||||||||||||||||||||
End of the period | $ | — | $ | 494 | |||||||||||||||||||||||||||||
-1 | In connection with the Company’s IPO in July 2014, warrants for convertible preferred stock were converted to warrants for common stock, resulting in the reclassification of the related redeemable convertible preferred stock warrant liability to additional paid-in capital. | ||||||||||||||||||||||||||||||||
The fair value of the convertible preferred stock warrants was determined using the option pricing method, the probability weighted expected return method or Black-Scholes option pricing model using the following assumptions: | |||||||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||||||
March 31, | |||||||||||||||||||||||||||||||||
2015 | 2014 | ||||||||||||||||||||||||||||||||
Expected life (years) | — | 2 | |||||||||||||||||||||||||||||||
Expected volatility | — | 46 | % | ||||||||||||||||||||||||||||||
Risk-free interest rate | — | 0.5 | % | ||||||||||||||||||||||||||||||
Dividend yield | — | 0 | % |
Equipment_Loans
Equipment Loans | 3 Months Ended | |
Mar. 31, 2015 | ||
Debt Disclosure [Abstract] | ||
Equipment Loans | 6 | Equipment Loans |
In September 2012, the Company entered into an equipment loan with an aggregate principal amount of $2.0 million, all of which was drawn down in December 2012. Payments were being made in monthly installments over a 36-month period with an annual interest rate of 5.1%. In August 2014, the amount outstanding under this equipment loan of $0.9 million was fully repaid. A total of $16,000 was recorded as interest expense during the three months ended March 31, 2014. | ||
In April 2013, the Company entered into a capital lease for a principal amount of $0.1 million. Payments were made in monthly installments over a 38-month period with an interest rate of 14.88%. In November 2014, the amount outstanding under this equipment loan of $59,000 was fully repaid. |
Convertible_Preferred_Stock_Wa
Convertible Preferred Stock Warrants | 3 Months Ended | |
Mar. 31, 2015 | ||
Text Block [Abstract] | ||
Convertible Preferred Stock Warrants | 7 | Convertible Preferred Stock Warrants |
In connection with the Company’s IPO in July 2014, the warrants for convertible preferred stock were converted to warrants for common stock, resulting in the reclassification of the related redeemable convertible preferred stock warrant liability of $0.4 million to additional paid-in capital. | ||
In January 2015, warrants issued in connection with a venture loan to purchase 47,554 shares of Series A convertible preferred stock were exercised for common stock through a cashless exercise provision. Net shares of 39,961 were issued and the remaining 7,593 shares were withheld for the exercise price. | ||
In connection with the execution of the loan and security agreement (“Loan Agreement”) with Silicon Valley Bank (“SVB”) in August 2013, warrants were issued to purchase the Company’s Series D convertible preferred stock. The Company cancelled the Loan Agreement in August 2014 and had not received any advances under the Loan Agreement. The warrants were exercisable for 5,803 shares of Series D convertible preferred stock at an exercise price of $6.89 per share. The initial fair value of the warrants issued was $10,000 and has been recognized as a convertible preferred stock warrant liability and interest expense. In February 2015, this warrant was exercised through a cashless exercise provision. Net shares of common stock of 4,024 were issued and the remaining 1,779 shares were withheld for the exercise price. | ||
In March 2014, warrants to purchase 4,076 shares of Series A convertible preferred stock were exercised through a cashless exercise provision. Net shares of 2,431 were issued and the remaining 1,645 shares were withheld for the exercise price. The outstanding convertible preferred stock was subsequently converted to common stock in connection with the Company’s IPO in July 2014. |
Stockbased_Compensation_Expens
Stock-based Compensation Expense | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||||||||
Stock-based Compensation Expense | 8 | Stock-based Compensation Expense | |||||||
2014 Equity Incentive Plan | |||||||||
Under the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), the number of shares of common stock reserved for issuance will automatically increase on January 1 of each year, beginning on January 1, 2015, and continuing through and including January 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company’s board of directors. On January 1, 2015, the total number of shares of common stock reserved for issuance increased by 701,328 shares to 5,451,328 shares. | |||||||||
A summary of the Company’s stock option activity and related information is as follows (options in thousands): | |||||||||
Three Months Ended | |||||||||
March 31, | |||||||||
2015 | |||||||||
Options | Price | ||||||||
Outstanding, beginning of period | 2,458 | $ | 4.84 | ||||||
Granted | 904 | 22.1 | |||||||
Exercised | (206 | ) | 1.72 | ||||||
Forfeited | (8 | ) | 16.31 | ||||||
Expired | (22 | ) | 6.66 | ||||||
Outstanding, end of period | 3,126 | 10 | |||||||
Vested and expected to vest | 2,927 | 9.64 | |||||||
Exercisable | 1,487 | 2.97 | |||||||
As of March 31, 2015, the aggregate pre-tax intrinsic value of options outstanding was $49.5 million and options outstanding and exercisable was $34.0 million, and the weighted-average remaining contractual term of options outstanding was 8.4 years and options outstanding and exercisable was 7.3 years. The aggregate pre-tax intrinsic value of options exercised was $4.6 million and $0.2 million during the three months ended March 31, 2015 and 2014, respectively. The aggregate pre-tax intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise. | |||||||||
Total stock-based compensation expense recognized, before taxes, is as follows (in thousands): | |||||||||
Three Months Ended | |||||||||
March 31, | |||||||||
2015 | 2014 | ||||||||
Cost of sales | $ | 39 | $ | 9 | |||||
Selling, general and administrative | 638 | 144 | |||||||
Research and development | 101 | 29 | |||||||
$ | 778 | $ | 182 | ||||||
As of March 31, 2015, the amount of unearned stock-based compensation currently estimated to be expensed from now through the year 2019 related to unvested employee stock-based payment awards was $12.2 million and the weighted average period over which the unearned stock-based compensation is expected to be recognized was 3.6 years. If there are any modifications or cancellations of the underlying unvested securities, the Company may be required to accelerate, increase or cancel any remaining unearned stock-based compensation expense. Future stock-based compensation expense and unearned stock-based compensation will increase to the extent that the Company grants additional share-based payments. | |||||||||
The Company estimates the fair value of stock-based compensation on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model determines the fair value of stock-based payment awards based on the fair market value of the Company’s common stock on the date of grant and is affected by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the fair market value of the Company’s common stock, volatility over the expected term of the awards and actual and projected employee stock option exercise behaviors. The Company has opted to use the “simplified method” for estimating the expected term of options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. Due to the Company’s limited operating history and a lack of company specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company generally selected companies with comparable characteristics to it, including enterprise value, stages of clinical development, risk profiles, position within the industry and with historical share price information sufficient to meet the expected life of the stock-based awards. The historical volatility data was computed using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the share-based payments. The Company will continue to analyze the historical stock price volatility and expected term assumptions as more historical data for the Company’s common stock becomes available. The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the Company’s stock options. The expected dividend assumption is based on the Company’s history of not paying dividends and its expectation that it will not declare dividends for the foreseeable future. | |||||||||
As stock-based compensation expense is based on awards ultimately expected to vest, the amount of expense has been reduced for estimated forfeitures. Potential forfeitures are estimated based on the Company’s historical forfeiture experience and an analysis of similar companies. To the extent actual forfeitures differ from the estimates, the Company records the difference as a cumulative adjustment in the period that the estimates are revised. | |||||||||
The fair value of the options granted to employees or directors during the three months ended March 31, 2015 and 2014, were estimated as of the grant date using the Black-Scholes model assuming the weighted average assumptions listed in the following table: | |||||||||
Three Months Ended | |||||||||
March 31, | |||||||||
2015 | 2014 | ||||||||
Expected life (years) | 6 | 6 | |||||||
Expected volatility | 49 | % | 60 | % | |||||
Risk-free interest rate | 1.6 | % | 1.8 | % | |||||
Dividend yield | 0 | % | 0 | % | |||||
Weighted average fair value | $ | 10.51 | $ | 3.44 | |||||
Option Modification | |||||||||
In April 2013, options held by the President and Chief Executive Officer, Ms. Earnhardt, a related party, were modified to permit exercise with promissory notes of up to $0.5 million. Under the terms of the notes, one quarter of the principal and interest was to be forgiven on each anniversary date of the note as long as Ms. Earnhardt remains the Company’s Chief Executive Officer. In addition, the entire principal and interest of the notes was to be forgiven on the earlier of an initial public offering or the closing of a liquidation event (as defined in the certificate of incorporation), in each case where total proceeds payable to the Company or its stockholders is greater than $200.0 million. The Company had the option to accelerate the maturity date if, at the Company’s reasonable discretion, such acceleration may be necessary due to any applicable law, rule or regulation, including, without limitation, the Sarbanes-Oxley Act of 2002. The economic effect of the modification was equivalent to converting options to purchase 0.6 million shares to a grant of restricted stock with four-year vesting and a contingent vesting acceleration provision. The incremental cost of the modification was $0.3 million, of which $7,000 and $13,000 was recognized during three months ended March 31, 2015 and 2014, respectively. | |||||||||
In June 2014, the entire principal amount and all accrued and unpaid interest of the loan was forgiven in full. In connection with the forgiveness of the note, the unamortized modification cost relating to the vested options of $0.2 million was immediately recognized. The remaining unamortized modification cost of $0.1 million will be amortized over the remaining vesting period. | |||||||||
2014 Employee Stock Purchase Plan | |||||||||
In July 2014, the Company’s board of directors approved the 2014 Employee Stock Purchase Plan (“2014 ESPP”). The 2014 ESPP became effective on the effective date of the IPO. A total of 496,092 shares are reserved for issuance under the 2014 ESPP. In March 2015, the Company approved the implementation of the 2014 ESPP to begin in May 2015. |
Net_Loss_per_Share
Net Loss per Share | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Earnings Per Share [Abstract] | |||||||||
Net Loss per Share | 9 | Net Loss per Share | |||||||
Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Because the Company has reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share for those periods as all potentially dilutive shares consisting of convertible preferred stock, stock options and warrants were antidilutive in those periods. | |||||||||
The Company allocates no loss to participating securities because the participating securities have no contractual obligation to share in the losses of the Company. The shares of the Company’s convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities. | |||||||||
Net loss per share was determined as follows (in thousands, except per share amounts): | |||||||||
Three Months Ended | |||||||||
March 31, | |||||||||
2015 | 2014 | ||||||||
Net loss | $ | (5,338 | ) | $ | (4,409 | ) | |||
Weighted average common stock outstanding (1) | 23,488 | 1,773 | |||||||
Net loss per share, basic and diluted | $ | (0.23 | ) | $ | (2.49 | ) | |||
-1 | In connection with the Company’s IPO in July 2014, the convertible preferred stock outstanding was converted into common stock on a one-for-one basis. | ||||||||
The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an antidilutive impact due to losses reported, in common stock equivalent shares (in thousands): | |||||||||
March 31, | |||||||||
2015 | 2014 | ||||||||
Convertible preferred stock outstanding (1) | — | 15,704 | |||||||
Convertible preferred stock warrants (1) | — | 53 | |||||||
Common stock options | 3,126 | 1,965 | |||||||
3,126 | 17,722 | ||||||||
-1 | In connection with the Company’s IPO in July 2014, the convertible preferred stock outstanding was converted into common stock and the convertible preferred stock warrants were converted into common stock warrants, both on a one-for-one basis. |
Commitments_and_Contingencies
Commitments and Contingencies | 3 Months Ended | |
Mar. 31, 2015 | ||
Commitments and Contingencies Disclosure [Abstract] | ||
Commitments and Contingencies | 10 | Commitments and Contingencies |
Contingencies | ||
In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. | ||
Indemnification | ||
The Company’s amended and restated certificate of incorporation contains provisions limiting the liability of directors, and its amended and restated bylaws provide that the Company will indemnify each of its directors to the fullest extent permitted under Delaware law. The Company’s amended and restated certificate of incorporation and amended and restated bylaws also provide its board of directors with discretion to indemnify its officers and employees when determined appropriate by the board. In addition, the Company has entered and expects to continue to enter into agreements to indemnify its directors and executive officers. | ||
Litigation | ||
The Company is not currently a party to any material legal proceedings. The Company may at times be involved in litigation and other legal claims in the ordinary course of business. When appropriate in the Company’s estimation, it may record reserves in its financial statements for pending litigation and other claims. |
Related_Parties
Related Parties | 3 Months Ended | |
Mar. 31, 2015 | ||
Related Party Transactions [Abstract] | ||
Related Parties | 11 | Related Parties |
In April 2013, options held by the President and Chief Executive Officer, Ms. Earnhardt, a related party, were modified to permit exercise with promissory notes of up to $0.5 million. Under the terms of the notes, one quarter of the principal and interest was to be forgiven on each anniversary date of the note as long as Ms. Earnhardt remained the Company’s Chief Executive Officer. In addition, the entire principal and interest of the notes was to be forgiven on the earlier of an initial public offering or the closing of a liquidation event (as defined in the certificate of incorporation), in each case where total proceeds payable to the Company or its stockholders is greater than $200.0 million. The Company had the option to accelerate the maturity date if, at the Company’s reasonable discretion, such acceleration may be necessary due to any applicable law, rule or regulation, including, without limitation, the Sarbanes-Oxley Act of 2002. The entire principal amount and all accrued and unpaid interest of the loan was forgiven in full in June 2014. | ||
In January 2007, the Company loaned amounts to its Chief Operation Officer, Mr. Kaufman, a related party, in connection with the commencement of his employment with the Company. The loan was evidenced by a promissory note for $0.3 million. This note bore interest at the applicable federal rate and interest was determined in accordance with Section 7872 of the Internal Revenue Code and has been reflected as income to Mr. Kaufman. Pursuant to the terms of the promissory note, provided Mr. Kaufman remained a continuous, full-time employee of the Company, repayment of the note was to begin after the third year of employment when 50% of his annual bonus would have been applied to the loan balance until the loan was paid in full. The note matures and becomes immediately due and payable within 30 days following the date on which Mr. Kaufman ceases, voluntarily or involuntarily, to be employed by the Company. No payment was received in the year ended December 31, 2011 since the Company did not pay an annual bonus in that year. In February 2011, the Company agreed to forgive Mr. Kaufman’s loan over three years, provided Mr. Kaufman remained employed by the Company, at the rate of $0.1 million annually in January 2012, 2013 and 2014. Mr. Kaufman’s note was fully forgiven in January 2014. | ||
In March 2009, the Company purchased three sinus irrigation tool patents from Medilyfe Inc., a Canadian corporation. A member of the Company’s Medical Advisory Board holds an executive-level position with Medilyfe Inc. The agreement called for a $40,000 payment upon execution of the agreement and an additional $35,000 upon the first anniversary of the agreement’s effective date in addition to the issuance of a warrant to purchase 43,750 shares of the Company’s common stock at $1.00 per share. | ||
The warrant vested fully upon grant and will expire April 7, 2019. The value of the warrant was $30,000 determined using the Black-Scholes model. The cost of the patents is included in research and development expense, since substantial research and development efforts were required at the time of the payment of these amounts and there was no alternative future use of the technology rights. A $35,000 cash payment was made in 2012, since one additional patent claim was allowed by the U.S. Patent Office. The Company recorded $35,000 in research and development expense related to this agreement for the year ended December 31, 2012. An additional $80,000 cash payment will be due upon the first achievement of net sales of products incorporating this technology exceeding $1.0 million in a given calendar year. Such additional payment was not owed as of March 31, 2015 and December 31, 2014, since this technology is unrelated to the Company’s current activities. |
Summary_of_Significant_Account1
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2015 | |
Accounting Policies [Abstract] | |
Basis of Preparation | Basis of Preparation |
The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”). | |
The interim financial data as of March 31, 2015, is unaudited and is not necessarily indicative of the results for the full year. In the opinion of the Company’s management, the interim data includes only normal and recurring adjustments necessary for a fair statement of the Company’s financial results for the three months ended March 31, 2015 and 2014. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. | |
The accompanying condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K (“Annual Report”) for the year ended December 31, 2014 filed with the SEC on March 11, 2015. | |
Financial Statements Reclassification | 1-for-4 Reverse Stock Split |
In July 2014, the board of directors and stockholders approved, and the Company filed, an amended and restated certificate of incorporation effecting a 1-for-4 reverse stock split of common stock and all convertible preferred stock. The par value of the common and convertible preferred stock was not adjusted as a result of the reverse stock split. All issued and outstanding common stock, convertible preferred stock, warrants for preferred stock, stock options and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. | |
Initial Public Offering | Initial Public Offering |
In July 2014, the Company completed its IPO by issuing 5,750,000 shares of common stock, including 750,000 shares pursuant to the full exercise by the underwriters of their option to purchase additional shares, at an offering price of $11.00 per share, for net proceeds of $55.8 million, after deducting underwriting discounts and commissions of $4.5 million and offering expenses of $3.0 million. In connection with the IPO, the Company’s outstanding shares of convertible preferred stock were automatically converted into 15,703,875 shares of common stock and warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for 53,357 shares of common stock, resulting in the reclassification of the related redeemable convertible preferred stock warrant liability of $0.4 million to additional paid-in capital. | |
Use of Estimates | Use of Estimates |
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its common stock valuation and related stock-based compensation, the valuations of the convertible preferred stock warrant liability, convertible preferred stock financing option, as well as certain accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. | |
Significant Accounting Policies | Significant Accounting Policies |
There have been no significant changes to the accounting policies during the three months ended March 31, 2015, as compared to the significant accounting policies described in Note 2 of the “Notes to Financial Statements” in the Company’s audited financial statements included in its Annual Report. | |
Comprehensive Loss | Comprehensive Loss |
Comprehensive loss comprises net loss and other comprehensive income (loss). The Company has no components of other comprehensive income (loss). Therefore net loss equals comprehensive loss for all periods presented. | |
Recent Accounting Pronouncements | Recent Accounting Pronouncements |
There have been no significant changes to the recent accounting pronouncements during the three months ended March 31, 2015, as compared to the recent accounting pronouncements described in Note 2 of the “Notes to Financial Statements” in the Company’s audited financial statements included in its Annual Report. |
Composition_of_Certain_Financi1
Composition of Certain Financial Statement Items (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||
Components of Inventory | Inventory (in thousands): | ||||||||
March 31, | December 31, | ||||||||
2015 | 2014 | ||||||||
Raw materials | $ | 709 | $ | 761 | |||||
Work-in-process | 146 | 141 | |||||||
Finished goods | 1,971 | 1,645 | |||||||
$ | 2,826 | $ | 2,547 | ||||||
Property and Equipment | Property and Equipment (in thousands): | ||||||||
March 31, | December 31, | ||||||||
2015 | 2014 | ||||||||
Computer equipment and software | $ | 616 | $ | 546 | |||||
Furniture and office equipment | 184 | 158 | |||||||
Laboratory equipment | 2,494 | 2,276 | |||||||
Leasehold improvements | 254 | 128 | |||||||
3,548 | 3,108 | ||||||||
Less: accumulated depreciation and amortization | (1,769 | ) | (1,634 | ) | |||||
$ | 1,779 | $ | 1,474 | ||||||
Cash_Cash_Equivalents_and_Shor1
Cash, Cash Equivalents and Short-term Investments (Tables) | 3 Months Ended | ||||||||||||||||||||||||||||||||
Mar. 31, 2015 | |||||||||||||||||||||||||||||||||
Cash and Cash Equivalents [Abstract] | |||||||||||||||||||||||||||||||||
Summary of Cash, Cash Equivalents and Available-for-Sale Investments by Type of Instrument | The following is a summary of cash, cash equivalents and short-term investments, available-for-sale, by type of instrument (in thousands): | ||||||||||||||||||||||||||||||||
March 31, | December 31, | ||||||||||||||||||||||||||||||||
2015 | 2014 | ||||||||||||||||||||||||||||||||
Amortized | Gross Unrealized | Estimated | Amortized | Gross Unrealized | Estimated | ||||||||||||||||||||||||||||
Cost | Gains | Losses | Fair Value | Cost | Gains | Losses | Fair Value | ||||||||||||||||||||||||||
Cash | $ | 2,360 | $ | — | $ | — | $ | 2,360 | $ | 1,971 | $ | — | $ | — | $ | 1,971 | |||||||||||||||||
Money market funds | 11,864 | — | — | 11,864 | 11,432 | — | — | 11,432 | |||||||||||||||||||||||||
Corporate debt securities | 24,938 | 1 | (6 | ) | 24,933 | 28,797 | 3 | (10 | ) | 28,790 | |||||||||||||||||||||||
Commercial paper | 3,744 | 5 | — | 3,749 | 6,243 | 7 | — | 6,250 | |||||||||||||||||||||||||
$ | 42,906 | $ | 6 | $ | (6 | ) | $ | 42,906 | $ | 48,443 | $ | 10 | $ | (10 | ) | $ | 48,443 | ||||||||||||||||
Reported as: | |||||||||||||||||||||||||||||||||
Cash and cash equivalents | $ | 14,224 | $ | 13,403 | |||||||||||||||||||||||||||||
Short-term investments, available-for-sale | 28,682 | 35,040 | |||||||||||||||||||||||||||||||
$ | 42,906 | $ | 48,443 | ||||||||||||||||||||||||||||||
Fair_Value_of_Financial_Instru1
Fair Value of Financial Instruments (Tables) | 3 Months Ended | ||||||||||||||||||||||||||||||||
Mar. 31, 2015 | |||||||||||||||||||||||||||||||||
Summary of Cash, Cash Equivalents and Available-for-Sale Investments Measured at Fair Value on Recurring Basis | The following is a summary of cash, cash equivalents and short-term investments, available-for-sale, by type of instrument measured at fair value on a recurring basis (in thousands): | ||||||||||||||||||||||||||||||||
March 31, | December 31, | ||||||||||||||||||||||||||||||||
2015 | 2014 | ||||||||||||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||||||||
Cash | $ | 2,360 | $ | — | $ | — | $ | 2,360 | $ | 1,971 | $ | — | $ | — | $ | 1,971 | |||||||||||||||||
Money market funds | 11,864 | — | — | 11,864 | 11,432 | — | — | 11,432 | |||||||||||||||||||||||||
Corporate debt securities | — | 24,933 | — | 24,933 | — | 28,790 | — | 28,790 | |||||||||||||||||||||||||
Commercial paper | — | 3,749 | — | 3,749 | — | 6,250 | — | 6,250 | |||||||||||||||||||||||||
$ | 14,224 | $ | 28,682 | $ | — | $ | 42,906 | $ | 13,403 | $ | 35,040 | $ | — | $ | 48,443 | ||||||||||||||||||
Reported as: | |||||||||||||||||||||||||||||||||
Cash and cash equivalents | $ | 14,224 | $ | 13,403 | |||||||||||||||||||||||||||||
Short-term investments, available-for-sale | 28,682 | 35,040 | |||||||||||||||||||||||||||||||
$ | 42,906 | $ | 48,443 | ||||||||||||||||||||||||||||||
Convertible Preferred Stock Warrants [Member] | |||||||||||||||||||||||||||||||||
Schedule of Changes in Estimated Fair Value using Valuations Classified as Level 3 | The following table sets forth a summary of the changes in the estimated fair value of the Company’s convertible preferred stock warrants, which represents financial instruments with valuations classified as Level 3. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. However, Level 3 financial instruments typically include, in addition to the unobservable inputs, observable inputs (that is, components that are actively quoted and can be validated to external sources). Accordingly, the expense in the table below includes changes in fair value due in part to observable factors that are part of the Level 3 methodology (in thousands): | ||||||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||||||
March 31, | |||||||||||||||||||||||||||||||||
2015 (1) | 2014 | ||||||||||||||||||||||||||||||||
Beginning of the period | $ | — | $ | 237 | |||||||||||||||||||||||||||||
Exercised | — | (29 | ) | ||||||||||||||||||||||||||||||
Change in fair value | — | 286 | |||||||||||||||||||||||||||||||
End of the period | $ | — | $ | 494 | |||||||||||||||||||||||||||||
-1 | In connection with the Company’s IPO in July 2014, warrants for convertible preferred stock were converted to warrants for common stock, resulting in the reclassification of the related redeemable convertible preferred stock warrant liability to additional paid-in capital. | ||||||||||||||||||||||||||||||||
Schedule of Fair Value Assumptions and Methodology | The fair value of the convertible preferred stock warrants was determined using the option pricing method, the probability weighted expected return method or Black-Scholes option pricing model using the following assumptions: | ||||||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||||||
March 31, | |||||||||||||||||||||||||||||||||
2015 | 2014 | ||||||||||||||||||||||||||||||||
Expected life (years) | — | 2 | |||||||||||||||||||||||||||||||
Expected volatility | — | 46 | % | ||||||||||||||||||||||||||||||
Risk-free interest rate | — | 0.5 | % | ||||||||||||||||||||||||||||||
Dividend yield | — | 0 | % |
Stockbased_Compensation_Expens1
Stock-based Compensation Expense (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||||||||
Summary of Stock Option Activity | A summary of the Company’s stock option activity and related information is as follows (options in thousands): | ||||||||
Three Months Ended | |||||||||
March 31, | |||||||||
2015 | |||||||||
Options | Price | ||||||||
Outstanding, beginning of period | 2,458 | $ | 4.84 | ||||||
Granted | 904 | 22.1 | |||||||
Exercised | (206 | ) | 1.72 | ||||||
Forfeited | (8 | ) | 16.31 | ||||||
Expired | (22 | ) | 6.66 | ||||||
Outstanding, end of period | 3,126 | 10 | |||||||
Vested and expected to vest | 2,927 | 9.64 | |||||||
Exercisable | 1,487 | 2.97 | |||||||
Summary of Stock Based Compensation Recognized Before Taxes | Total stock-based compensation expense recognized, before taxes, is as follows (in thousands): | ||||||||
Three Months Ended | |||||||||
March 31, | |||||||||
2015 | 2014 | ||||||||
Cost of sales | $ | 39 | $ | 9 | |||||
Selling, general and administrative | 638 | 144 | |||||||
Research and development | 101 | 29 | |||||||
$ | 778 | $ | 182 | ||||||
Summary of Weighted Average Assumptions Used to Estimate Options Using Black-Scholes Model | The fair value of the options granted to employees or directors during the three months ended March 31, 2015 and 2014, were estimated as of the grant date using the Black-Scholes model assuming the weighted average assumptions listed in the following table: | ||||||||
Three Months Ended | |||||||||
March 31, | |||||||||
2015 | 2014 | ||||||||
Expected life (years) | 6 | 6 | |||||||
Expected volatility | 49 | % | 60 | % | |||||
Risk-free interest rate | 1.6 | % | 1.8 | % | |||||
Dividend yield | 0 | % | 0 | % | |||||
Weighted average fair value | $ | 10.51 | $ | 3.44 |
Net_Loss_per_Share_Tables
Net Loss per Share (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Earnings Per Share [Abstract] | |||||||||
Schedule of Net Loss Per Share | Net loss per share was determined as follows (in thousands, except per share amounts): | ||||||||
Three Months Ended | |||||||||
March 31, | |||||||||
2015 | 2014 | ||||||||
Net loss | $ | (5,338 | ) | $ | (4,409 | ) | |||
Weighted average common stock outstanding (1) | 23,488 | 1,773 | |||||||
Net loss per share, basic and diluted | $ | (0.23 | ) | $ | (2.49 | ) | |||
-1 | In connection with the Company’s IPO in July 2014, the convertible preferred stock outstanding was converted into common stock on a one-for-one basis. | ||||||||
Schedule of Potentially Dilutive Securities Outstanding Excluded from the Computations of Diluted Weighted Average Shares Outstanding | The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an antidilutive impact due to losses reported, in common stock equivalent shares (in thousands): | ||||||||
March 31, | |||||||||
2015 | 2014 | ||||||||
Convertible preferred stock outstanding (1) | — | 15,704 | |||||||
Convertible preferred stock warrants (1) | — | 53 | |||||||
Common stock options | 3,126 | 1,965 | |||||||
3,126 | 17,722 | ||||||||
-1 | In connection with the Company’s IPO in July 2014, the convertible preferred stock outstanding was converted into common stock and the convertible preferred stock warrants were converted into common stock warrants, both on a one-for-one basis. |
Organization_Additional_Inform
Organization - Additional Information (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||
Cash, cash equivalents and short-term investments | $42,900,000 | ||
Accumulated deficit | ($101,959,000) | ($96,621,000) | [1] |
[1] | Amounts have been derived from the December 31, 2014 audited financial statements included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. |
Summary_of_Significant_Account2
Summary of Significant Accounting Policies - Additional Information (Detail) (USD $) | 1 Months Ended | 3 Months Ended |
In Millions, except Share data, unless otherwise specified | Jul. 31, 2014 | Mar. 31, 2015 |
Subsidiary, Sale of Stock [Line Items] | ||
Reverse stock split, ratio | 0.25 | |
Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital | $0.40 | |
Common Stock [Member] | ||
Subsidiary, Sale of Stock [Line Items] | ||
Reverse stock split | 1-for-4 reverse stock split | |
Common Stock [Member] | Initial Public Offering [Member] | ||
Subsidiary, Sale of Stock [Line Items] | ||
Number of shares issued | 5,750,000 | |
Common stock issued during period, price per share | $11 | |
Net proceeds from initial public offering | 55.8 | |
Underwriting discounts and commissions | 4.5 | |
Initial public offering, expenses | 3 | |
Convertible preferred stock converted into shares of common stock | 15,703,875 | |
Warrants exercisable for common stock shares | 53,357 | |
Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital | $0.40 | |
Common Stock [Member] | Over-Allotment Option [Member] | ||
Subsidiary, Sale of Stock [Line Items] | ||
Number of shares issued | 750,000 |
Composition_of_Certain_Financi2
Composition of Certain Financial Statement Items - Components of Inventory (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 | |
In Thousands, unless otherwise specified | |||
Inventory Disclosure [Abstract] | |||
Raw materials | $709 | $761 | |
Work-in-process | 146 | 141 | |
Finished goods | 1,971 | 1,645 | |
Inventory, net | $2,826 | $2,547 | [1] |
[1] | Amounts have been derived from the December 31, 2014 audited financial statements included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. |
Composition_of_Certain_Financi3
Composition of Certain Financial Statement Items - Property and Equipment (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 | |
In Thousands, unless otherwise specified | |||
Property, Plant and Equipment [Line Items] | |||
Plant and equipment, gross | $3,548 | $3,108 | |
Less: accumulated depreciation and amortization | -1,769 | -1,634 | |
Plant and equipment, net | 1,779 | 1,474 | [1] |
Computer Equipment [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Plant and equipment, gross | 616 | 546 | |
Furniture and Fixtures [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Plant and equipment, gross | 184 | 158 | |
Equipment [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Plant and equipment, gross | 2,494 | 2,276 | |
Leasehold Improvements [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Plant and equipment, gross | $254 | $128 | |
[1] | Amounts have been derived from the December 31, 2014 audited financial statements included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. |
Composition_of_Certain_Financi4
Composition of Certain Financial Statement Items - Additional information (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Statement of Financial Position [Abstract] | ||
Depreciation and capital lease amortization expenses | $140 | $135 |
Cash_Cash_Equivalents_and_Shor2
Cash, Cash Equivalents and Short-term Investments - Summary of Cash, Cash Equivalents and Available-for-Sale Investments by Type of Instrument (Detail) (USD $) | 3 Months Ended | 12 Months Ended |
In Thousands, unless otherwise specified | Mar. 31, 2015 | Dec. 31, 2014 |
Net Investment [Line Items] | ||
Cash, cash equivalents and available-for-sale investments, Amortized Cost | $42,906 | $48,443 |
Cash, cash equivalents and available-for-sale investments, Gross Unrealized Gains | 6 | 10 |
Cash, cash equivalents and available-for-sale investments, Gross Unrealized Losses | -6 | -10 |
Cash, cash equivalents and available-for-sale investments, Estimated Fair Value | 42,906 | 48,443 |
Cash and Cash Equivalents [Member] | ||
Net Investment [Line Items] | ||
Cash, cash equivalents and available-for-sale investments, Estimated Fair Value | 14,224 | 13,403 |
Short-term investments, available-for-sale [Member] | ||
Net Investment [Line Items] | ||
Cash, cash equivalents and available-for-sale investments, Estimated Fair Value | 28,682 | 35,040 |
Cash [Member] | ||
Net Investment [Line Items] | ||
Cash, cash equivalents and available-for-sale investments, Amortized Cost | 2,360 | 1,971 |
Cash, cash equivalents and available-for-sale investments, Estimated Fair Value | 2,360 | 1,971 |
Money Market Funds [Member] | ||
Net Investment [Line Items] | ||
Cash, cash equivalents and available-for-sale investments, Amortized Cost | 11,864 | 11,432 |
Cash, cash equivalents and available-for-sale investments, Estimated Fair Value | 11,864 | 11,432 |
Corporate Debt Securities [Member] | ||
Net Investment [Line Items] | ||
Cash, cash equivalents and available-for-sale investments, Amortized Cost | 24,938 | 28,797 |
Cash, cash equivalents and available-for-sale investments, Gross Unrealized Gains | 1 | 3 |
Cash, cash equivalents and available-for-sale investments, Gross Unrealized Losses | -6 | -10 |
Cash, cash equivalents and available-for-sale investments, Estimated Fair Value | 24,933 | 28,790 |
Commercial Paper [Member] | ||
Net Investment [Line Items] | ||
Cash, cash equivalents and available-for-sale investments, Amortized Cost | 3,744 | 6,243 |
Cash, cash equivalents and available-for-sale investments, Gross Unrealized Gains | 5 | 7 |
Cash, cash equivalents and available-for-sale investments, Estimated Fair Value | $3,749 | $6,250 |
Cash_Cash_Equivalents_and_Shor3
Cash, Cash Equivalents and Short-term Investments - Additional Information (Detail) (USD $) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2015 | Dec. 31, 2014 | |
Investments Schedule [Abstract] | ||
Investments with a maturity of greater than one year | $0 | $0 |
Other-than-temporary impairment charges | $0 | $0 |
Fair_Value_of_Financial_Instru2
Fair Value of Financial Instruments - Summary of Cash, Cash Equivalents and Short-Term Investments, Available-for-Sale, by Type of Instrument (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Thousands, unless otherwise specified | ||
Net Investment [Line Items] | ||
Short-term investments | $42,906 | $48,443 |
Cash and Cash Equivalents [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 14,224 | 13,403 |
Short-term investments, available-for-sale [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 28,682 | 35,040 |
Cash [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 2,360 | 1,971 |
Money Market Funds [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 11,864 | 11,432 |
Corporate Debt Securities [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 24,933 | 28,790 |
Commercial Paper [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 3,749 | 6,250 |
Fair Value on Recurring Basis [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 42,906 | 48,443 |
Fair Value on Recurring Basis [Member] | Cash and Cash Equivalents [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 14,224 | 13,403 |
Fair Value on Recurring Basis [Member] | Short-term investments, available-for-sale [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 28,682 | 35,040 |
Fair Value on Recurring Basis [Member] | Cash [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 2,360 | 1,971 |
Fair Value on Recurring Basis [Member] | Money Market Funds [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 11,864 | 11,432 |
Fair Value on Recurring Basis [Member] | Corporate Debt Securities [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 24,933 | 28,790 |
Fair Value on Recurring Basis [Member] | Commercial Paper [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 3,749 | 6,250 |
Level 1 [Member] | Fair Value on Recurring Basis [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 14,224 | 13,403 |
Level 1 [Member] | Fair Value on Recurring Basis [Member] | Cash [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 2,360 | 1,971 |
Level 1 [Member] | Fair Value on Recurring Basis [Member] | Money Market Funds [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 11,864 | 11,432 |
Level 2 [Member] | Fair Value on Recurring Basis [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 28,682 | 35,040 |
Level 2 [Member] | Fair Value on Recurring Basis [Member] | Corporate Debt Securities [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | 24,933 | 28,790 |
Level 2 [Member] | Fair Value on Recurring Basis [Member] | Commercial Paper [Member] | ||
Net Investment [Line Items] | ||
Short-term investments | $3,749 | $6,250 |
Fair_Value_of_Financial_Instru3
Fair Value of Financial Instruments - Additional Information (Detail) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
Fair Value Disclosures [Abstract] | ||
Transfer of assets from level 1 to level 2 | $0 | $0 |
Transfer of liabilities from level 1 to level 2 | 0 | 0 |
Transfer of assets from level 2 to level 1 | 0 | 0 |
Transfer of liabilities from level 2 to level 1 | $0 | $0 |
Fair_Value_of_Financial_Instru4
Fair Value of Financial Instruments - Schedule of Changes in Estimated Fair Value using Valuations Classified as Level 3 - Convertible Preferred Stock Warrant Liability (Detail) (USD $) | 3 Months Ended | ||
Mar. 31, 2015 | Mar. 31, 2014 | ||
Class of Warrant or Right [Line Items] | |||
Change in fair value | $286,000 | ||
Convertible Preferred Stock [Member] | Level 3 [Member] | |||
Class of Warrant or Right [Line Items] | |||
Beginning of the period | [1] | 237,000 | |
Exercised | [1] | -29,000 | |
Change in fair value | [1] | 286,000 | |
End of the period | [1] | $494,000 | |
[1] | In connection with the Company's IPO in July 2014, warrants for convertible preferred stock were converted to warrants for common stock, resulting in the reclassification of the related redeemable convertible preferred stock warrant liability to additional paid-in capital. |
Fair_Value_of_Financial_Instru5
Fair Value of Financial Instruments - Summary of Weighted Average Assumptions Used to Estimate Options Using Black-Scholes Model (Detail) (Convertible Preferred Stock Warrants [Member]) | 3 Months Ended |
Mar. 31, 2014 | |
Convertible Preferred Stock Warrants [Member] | |
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] | |
Expected life (years) | 2 years |
Expected volatility | 46.00% |
Risk-free interest rate | 0.50% |
Dividend yield | 0.00% |
Equipment_Loans_Additional_Inf
Equipment Loans - Additional Information (Detail) (USD $) | 3 Months Ended | |||||
Mar. 31, 2015 | Mar. 31, 2014 | Aug. 31, 2014 | Dec. 31, 2012 | Nov. 30, 2014 | Apr. 30, 2013 | |
Equipment Loan [Member] | ||||||
Capital Leased Assets [Line Items] | ||||||
Aggregate principal amount under loan facility | $2,000,000 | |||||
Interest rate | 5.10% | |||||
Interest expense | 16,000 | |||||
Amount outstanding | 900,000 | |||||
Frequency of monthly payments | 36-month | |||||
Capital Lease Obligations [Member] | ||||||
Capital Leased Assets [Line Items] | ||||||
Interest rate | 14.88% | |||||
Amount outstanding | 59,000 | |||||
Frequency of monthly payments | 38-month | |||||
Capital lease obligation | $100,000 |
Convertible_Preferred_Stock_Wa1
Convertible Preferred Stock Warrants - Additional Information (Detail) (USD $) | 1 Months Ended | |||||||
In Millions, except Share data, unless otherwise specified | Jul. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2015 | Dec. 31, 2014 | Feb. 28, 2015 | Aug. 31, 2013 | Jan. 31, 2015 | |
Class of Warrant or Right [Line Items] | ||||||||
Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital | $0.40 | |||||||
Net common stock shares issued | 23,633,000 | 23,379,000 | [1] | |||||
Shares withheld due to exercise price | 0 | 0 | [1] | |||||
Net preferred stock shares issued | 0 | 0 | [1] | |||||
Equipment Loan Warrant [Member] | ||||||||
Class of Warrant or Right [Line Items] | ||||||||
Shares withheld due to exercise price | 1,645 | |||||||
Number of shares of Series A convertible preferred stock exercised though a cashless exercise of warrants | 4,076 | |||||||
Net preferred stock shares issued | 2,431 | |||||||
Loan Origination Commitments [Member] | ||||||||
Class of Warrant or Right [Line Items] | ||||||||
Warrants exercisable for common stock shares | 5,803 | |||||||
Net common stock shares issued | 4,024 | |||||||
Shares withheld due to exercise price | 1,779 | |||||||
Warrants exercise price per share | $6.89 | |||||||
Initial fair value | $10,000 | |||||||
Venture Loan [Member] | ||||||||
Class of Warrant or Right [Line Items] | ||||||||
Warrants exercisable for common stock shares | 47,554 | |||||||
Net common stock shares issued | 39,961 | |||||||
Shares withheld due to exercise price | 7,593 | |||||||
[1] | Amounts have been derived from the December 31, 2014 audited financial statements included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. |
Recovered_Sheet1
Stock-Based Compensation Expense - Additional Information (Detail) (USD $) | 3 Months Ended | 0 Months Ended | 1 Months Ended | ||
Mar. 31, 2015 | Mar. 31, 2014 | Jan. 01, 2015 | Apr. 30, 2013 | Jul. 23, 2014 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Aggregate pre-tax intrinsic value of options outstanding | $49,500,000 | ||||
Aggregate pre-tax intrinsic value of options outstanding and exercisable | 34,000,000 | ||||
Weighted-average remaining contractual term of options outstanding | 8 years 4 months 24 days | ||||
Weighted-average remaining contractual term of options exercisable | 7 years 3 months 18 days | ||||
Aggregate pre-tax intrinsic value of options exercised | 4,600,000 | 200,000 | |||
Unearned stock-based compensation | 12,200,000 | ||||
Weighted average period for unearned stock-based compensation to be recognized | 3 years 7 months 6 days | ||||
Conversion of options to grant restricted stock | 600,000 | ||||
Vesting period | 4 years | ||||
Incremental cost of modification | 300,000 | ||||
Incremental cost recognized | 7,000 | 13,000 | |||
Unamortized modification cost related to vested options | 200,000 | ||||
Remaining unamortized cost yet to be amortized | 100,000 | ||||
2014 Employee Stock Purchase Plan [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Shares reserved for issuance | 496,092 | ||||
2014 Equity Incentive Plan [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Percentage of shares outstanding | 3.00% | ||||
Common Stock, Capital Shares Reserved for Future Issuance, increase during period | 701,328 | ||||
Shares reserved for issuance | 5,451,328 | ||||
Promissory Notes [Member] | President And Chief Executive Officer [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Options modified to permit exercise with promissory notes | 500,000 | ||||
Minimum [Member] | Promissory Notes [Member] | President And Chief Executive Officer [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Liquidation event threshold representing total proceeds payable to the Company | $200,000,000 |
Recovered_Sheet2
Stock-Based Compensation Expense - Summary of Stock Option Activity (Detail) (USD $) | 3 Months Ended |
In Thousands, except Per Share data, unless otherwise specified | Mar. 31, 2015 |
Equity [Abstract] | |
Options outstanding, beginning of period | 2,458 |
Options granted | 904 |
Options exercised | -206 |
Options forfeited | -8 |
Options expired | -22 |
Options outstanding, end of period | 3,126 |
Options vested and expected to vest | 2,927 |
Options exercisable | 1,487 |
Options price, outstanding, beginning of period | $4.84 |
Options price, granted | $22.10 |
Options price, exercised | $1.72 |
Options price, forfeited | $16.31 |
Option price, expired | $6.66 |
Options price, outstanding, end of period | $10 |
Options price, vested and expected to vest | $9.64 |
Options price, exercisable | $2.97 |
StockBased_Compensation_Expens2
Stock-Based Compensation Expense - Summary of Stock Based Compensation Recognized Before Taxes (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | $778 | $182 |
Cost of Sales [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | 39 | 9 |
Selling, General and Administrative Expenses [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | 638 | 144 |
Research and Development Expense [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | $101 | $29 |
StockBased_Compensation_Expens3
Stock-Based Compensation Expense - Summary of Weighted Average Assumptions Used to Estimate Options Using Black-Scholes Model (Detail) (USD $) | 3 Months Ended | |
Mar. 31, 2015 | Mar. 31, 2014 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||
Expected life (years) | 6 years | 6 years |
Expected volatility | 49.00% | 60.00% |
Risk-free interest rate | 1.60% | 1.80% |
Dividend yield | 0.00% | 0.00% |
Weighted average fair value | $10.51 | $3.44 |
Net_Loss_Per_Share_Additional_
Net Loss Per Share - Additional Information (Detail) (USD $) | 3 Months Ended |
Mar. 31, 2015 | |
Accounting Policies [Abstract] | |
Loss allocated to participating securities | $0 |
Contractual obligation | $0 |
Net_Loss_Per_Share_Schedule_of
Net Loss Per Share - Schedule of Net Loss Per Share (Detail) (USD $) | 3 Months Ended | |||
In Thousands, except Per Share data, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 | ||
Earnings Per Share [Abstract] | ||||
Net loss | ($5,338) | ($4,409) | ||
Weighted average common stock outstanding | 23,488 | [1] | 1,773 | [1] |
Net loss per share, basic and diluted | ($0.23) | ($2.49) | ||
[1] | In connection with the Company's IPO in July 2014, the convertible preferred stock outstanding was converted into common stock on a one-for-one basis. |
Net_Loss_Per_Share_Schedule_of1
Net Loss Per Share - Schedule of Net Loss Per Share (Parenthetical) (Detail) (Common Stock [Member]) | 3 Months Ended |
Mar. 31, 2015 | |
Common Stock [Member] | |
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] | |
Convertible preferred stock was converted to common stock | One-for-one |
Net_Loss_Per_Share_Schedule_of2
Net Loss Per Share - Schedule of Potentially Dilutive Securities Outstanding Excluded from the Computations of Diluted Weighted Average Shares Outstanding (Detail) | 3 Months Ended | ||
In Thousands, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive securities excluded from computation of diluted weighted average shares outstanding | 3,126 | 17,722 | |
Common Stock Options [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive securities excluded from computation of diluted weighted average shares outstanding | 3,126 | 1,965 | |
Convertible Preferred Stock [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive securities excluded from computation of diluted weighted average shares outstanding | 15,704 | [1] | |
Convertible Preferred Stock Warrants [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive securities excluded from computation of diluted weighted average shares outstanding | 53 | [1] | |
[1] | In connection with the Company's IPO in July 2014, the convertible preferred stock outstanding was converted into common stock and the convertible preferred stock warrants were converted into common stock warrants, both on a one-for-one basis. |
Net_Loss_Per_Share_Schedule_of3
Net Loss Per Share - Schedule of Potentially Dilutive Securities Outstanding Excluded from the Computations of Diluted Weighted Average Shares Outstanding (Parenthetical) (Detail) (Common Stock [Member]) | 3 Months Ended |
Mar. 31, 2015 | |
Common Stock [Member] | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |
Convertible preferred stock was converted to common stock | One-for-one |
Related_Parties_Additional_Inf
Related Parties - Additional Information (Detail) (USD $) | 3 Months Ended | 1 Months Ended | 12 Months Ended | 3 Months Ended | 1 Months Ended | 12 Months Ended | ||||
Mar. 31, 2014 | Mar. 31, 2009 | Dec. 31, 2012 | Mar. 31, 2015 | Apr. 30, 2013 | Jan. 31, 2014 | Jan. 31, 2013 | Jan. 31, 2012 | Dec. 31, 2011 | Jan. 31, 2007 | |
Patents | ||||||||||
Related Party Transaction [Line Items] | ||||||||||
Forgiveness of notes receivable from related party | $100,000 | |||||||||
Affiliated Entity [Member] | ||||||||||
Related Party Transaction [Line Items] | ||||||||||
Milestone payments upon execution of agreement | 40,000 | |||||||||
Additional milestone payments | 35,000 | |||||||||
Number of irrigation tool patents purchased | 3 | |||||||||
Value of warrant at the date of grant | 30,000 | |||||||||
Additional cash payments due upon achievement of net sales | 80,000 | |||||||||
Cash payment | 35,000 | |||||||||
Affiliated Entity [Member] | Minimum [Member] | ||||||||||
Related Party Transaction [Line Items] | ||||||||||
Threshold of net sales of products incorporating technology, that triggers a cash payment | 1,000,000 | |||||||||
Affiliated Entity [Member] | Warrant [Member] | ||||||||||
Related Party Transaction [Line Items] | ||||||||||
Shares Outstanding | 43,750 | |||||||||
Warrant to purchase common stock per share value | $1 | |||||||||
Warrant vested upon grant, Expiration date | 7-Apr-19 | |||||||||
Promissory Notes [Member] | President And Chief Executive Officer [Member] | ||||||||||
Related Party Transaction [Line Items] | ||||||||||
Options modified to permit exercise with promissory notes | 500,000 | |||||||||
Terms of related party transaction description | Under the terms of the notes, one quarter of the principal and interest was to be forgiven on each anniversary date of the note as long as Ms. Earnhardt remained the Companybs Chief Executive Officer. In addition, the entire principal and interest of the notes was to be forgiven on the earlier of an initial public offering or the closing of a liquidation event (as defined in the certificate of incorporation) where total proceeds payable to the Company or its stockholders is greater than $200.0 million. The Company had the option to accelerate the maturity date if, at the Companybs reasonable discretion, such acceleration may be necessary due to any applicable law, rule or regulation, including, without limitation, the Sarbanes-Oxley Act of 2002. | |||||||||
Promissory Notes [Member] | President And Chief Executive Officer [Member] | Maximum [Member] | ||||||||||
Related Party Transaction [Line Items] | ||||||||||
Options modified to permit exercise with promissory notes | 500,000 | |||||||||
Promissory Notes [Member] | President And Chief Executive Officer [Member] | Minimum [Member] | ||||||||||
Related Party Transaction [Line Items] | ||||||||||
Liquidation event threshold representing total proceeds payable to the Company | 200,000,000 | |||||||||
Promissory Notes [Member] | Chief Operating Officer [Member] | ||||||||||
Related Party Transaction [Line Items] | ||||||||||
Terms of related party transaction description | Pursuant to the terms of the promissory note, provided Mr. Kaufman remained a continuous, full-time employee of the Company, repayment of the note was to begin after the third year of employment when 50% of his annual bonus would have been applied to the loan balance until the loan was paid in full. The note matures and becomes immediately due and payable within 30 days following the date on which Mr. Kaufman ceases, voluntarily or involuntarily, to be employed by the Company. | |||||||||
Note issued to related party | 300,000 | |||||||||
Payment of note received | 0 | |||||||||
Forgiveness of notes receivable from related party | $100,000 | $100,000 | $100,000 | |||||||
Debt forgiveness term | 3 years |